16
1
8
↑16
↓1
—8
Evidence suggests Melatonin mayincreasePerformance.
23 studies (25 claims)
Moderate consensus
Typical effective dose 4 (3–5.75) mgacross 8 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| oral melatonin supplementation | Increases - most commonly reported adverse events relating to | fatigue, mood, or psychomotor and neurocognitive performance | Human | humans | Not specified in the abstract. | Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence.cited 89× |
| melatonin | Increases - trend for beneficial effect | change in MSFC performance | Human | relapsing-remitting MS (RRMS) patients receiving once weekly interferon beta | 3 mg/day | Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.cited 22× |
| melatonin | Increases - effective in improving | daily performance | Human | healthy children suffering from insomnia | — | The effect of treatment with melatonin on primary school aged children with difficulty in initiation and maintenance of sleep.cited 2× |
| melatonin | Decreases - caused | performance decrements | Human | twelve adults (five female individuals) aged 20-45 years | 3 mg of melatonin taken 11 h before baseline sleep midpoint on the first treatment day and 1 h earlier each subsequent day. | Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance.cited 26× |
| melatonin | No effect - no difference between intervention and control groups | performance of activities of daily living (ADLs) | Human | patients with AD | Not specified for light therapy. | Pharmacotherapies for sleep disturbances in Alzheimer's disease.cited 72× |
| melatonin | No effect - no effect | performance of activities of daily living (ADL) | Human | patients with AD who were identified as having a sleep disturbance | Not specified for light therapy. | Pharmacotherapies for sleep disturbances in dementia.cited 88× |
| Melatonin | Increases - maximizing sports performance | sports performance | Human | athletes | Not specified | Medications for Sleep Schedule Adjustments in Athletes.cited 7× |
| exogenous melatonin | Increases - plays a crucial role in enhancing | reproductive performance | Animal | small ruminants | — | Exogenous melatonin ameliorates embryo-maternal cross-talk in early pregnancy in sheep. |
| daily evening melatonin | Increases - improves | sleep quality and cognitive performance | Human | MCI | Not specified | The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease.cited 17× |
| add-on prolonged-release melatonin (PRM) (2 mg) | Increases - had significantly better cognitive performance | cognitive performance | Human | patients diagnosed with mild to moderate AD | 2 mg nightly | Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.cited 151× |
| 3 mg time-release melatonin | No effect - no statistically significant differences | neurocognitive performance | Human | survivors from the St. Jude Lifetime Cohort | 3 mg time-release melatonin. | A randomized double-blind placebo-controlled trial of the effectiveness of melatonin on neurocognition and sleep in survivors of childhood cancer.cited 3× |
| melatonin supplementation | No effect - did not affect | aerobic performance relative to time trial | Human | healthy subjects | Not specified | Is melatonin as an ergogenic hormone a myth? a systematic review and meta-analysis.cited 4× |
| melatonin supplementation | No effect - did not affect | aerobic performance relative to VO | Human | healthy subjects | Not specified | Is melatonin as an ergogenic hormone a myth? a systematic review and meta-analysis.cited 4× |
| melatonin supplementation | Increases - had a significant impact on enhancing | antioxidant performance | Human | — | — | Melatonin effectiveness in amelioration of oxidative stress and strengthening of antioxidant defense system: Findings from a systematic review and dose-response meta-analysis of controlled clinical trials.cited 23× |
| melatonin supplementation | No effect - did not significantly change | patient determined disease steps (PDDS) and performance scales (PS) scores | Human | patients with relapsing forms of multiple sclerosis (RMS) | 3 mg or 5 mg daily. | Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis. |
| melatonin supplementation | No effect - has effects on physical performance | physical performance | Human | — | 5-8 mg | The Effects of Melatonin Supplementation on Professional Football Player Performance: A Systematic Review.cited 6× |
| melatonin supplementation | No effect - direct effects have not been demonstrated | physical performance | Human | — | 5-8 mg | The Effects of Melatonin Supplementation on Professional Football Player Performance: A Systematic Review.cited 6× |
| melatonin supplementation | Increases - promising data were found regarding the potential benefits | sports performance | Human | highly trained athletes | 5 mg to 100 mg, administered before or after exercise | Impact of Melatonin Supplementation on Sports Performance and Circulating Biomarkers in Highly Trained Athletes: A Systematic Review of Randomized Controlled Trials.cited 9× |
| melatonin supplementation | Increases - an indirect effect | sports performance | Human | highly trained athletes | 5 mg to 100 mg, administered before or after exercise | Impact of Melatonin Supplementation on Sports Performance and Circulating Biomarkers in Highly Trained Athletes: A Systematic Review of Randomized Controlled Trials.cited 9× |
| 5-mg melatonin supplement | No effect - does not affect | 32.2-km cycling time trial performance | Human | trained male subjects | 5 mg, administered once 15 minutes before exercise. | Consumption of a 5-mg Melatonin Supplement Does Not Affect 32.2-km Cycling Time Trial Performance.cited 11× |
| 3 mg melatonin | No effect - differences | cognitive performance | Human | adult participants, aged 50 and older, undergoing elective or semi-elective cardiac surgery | 3 mg melatonin administered daily. | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial.cited 10× |
| genetic deletion of melatonin receptors | Increases - produces | mice with enhanced cognitive and motor performance | Animal | transgenic mice lacking both melatonin receptors | — | Genetic deletion of MT₁/MT₂ melatonin receptors enhances murine cognitive and motor performance. |
| genetic deletion of melatonin receptors | Increases - found | Significant improvement in cognitive performance | Animal | melatonin receptor-deficient mice | — | Genetic deletion of MT₁/MT₂ melatonin receptors enhances murine cognitive and motor performance. |
| supplementation of melatonin | Increases - has yielded significant beneficial effects | memory performance | Human | — | Not specified | Psychoneuroendocrine interventions aimed at attenuating immunosenescence: a review.cited 13× |